Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 2023 ASCO Gastrointestinal Cancers Symposium will host world-renowned experts in gastrointestinal cancers and this international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of gastrointestinal cancers.
Watch exclusive interviews from ASCO GI 2023 to keep up to date with the latest in gastrointestinal cancers!
#ESMO26 | Xing Zhang shares results from a Phase II study of nab-paclitaxel + pegylated liposomal doxorubicin in advanced or unresectable malignant vascular tumors, including #angiosarcoma 💉📈
The combination achieved an ORR of around 50% and a PFS of around 8 months, and
This #lungcancer awareness month, Joshua Sabari explores emerging combination strategies, balancing efficacy with toxicity and patient-reported outcomes, and the potential of brain-penetrant TKIs such as NVL-330.
Want to gain insight into the role of total neoadjuvant therapy in locally advanced #RectalCancer? 🩺💪
Check out our recent interview with Sara Lonardi (@sara_lonardi1) from #ESSO45, where she explains how delivering #chemotherapy and #radiotherapy before surgery offers a more
At #ESMO26, Ariane Steindl shares findings from a study of around 150 patients with progressive #BrainMetastases, in which those who received #radiotherapy before progression had lower TIL infiltration and higher levels of the immunosuppressive marker FOXP3 🧠☢️
The 2023 ASCO Gastrointestinal Cancers Symposium will host world-renowned experts in gastrointestinal cancers and this international scientific symposium allows for important interactions and exchanges between basic scientists and clinicians devoted to improved diagnosis and treatment of gastrointestinal cancers.
Watch exclusive interviews from ASCO GI 2023 to keep up to date with the latest in gastrointestinal cancers!
#ESMO26 | Xing Zhang shares results from a Phase II study of nab-paclitaxel + pegylated liposomal doxorubicin in advanced or unresectable malignant vascular tumors, including #angiosarcoma 💉📈
The combination achieved an ORR of around 50% and a PFS of around 8 months, and
This #lungcancer awareness month, Joshua Sabari explores emerging combination strategies, balancing efficacy with toxicity and patient-reported outcomes, and the potential of brain-penetrant TKIs such as NVL-330.
Want to gain insight into the role of total neoadjuvant therapy in locally advanced #RectalCancer? 🩺💪
Check out our recent interview with Sara Lonardi (@sara_lonardi1) from #ESSO45, where she explains how delivering #chemotherapy and #radiotherapy before surgery offers a more
At #ESMO26, Ariane Steindl shares findings from a study of around 150 patients with progressive #BrainMetastases, in which those who received #radiotherapy before progression had lower TIL infiltration and higher levels of the immunosuppressive marker FOXP3 🧠☢️